idelalisib: Clinical Trials

14 trials of idelalisib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated, 2 active not recruiting, 2 completed, 2 recruiting. 14 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 314Terminated 7, Active not recruiting 2, Completed 2, Recruiting 2, Withdrawn 1

Follow idelalisib: new trials by email Literature Review of idelalisib trials Research Report on idelalisib

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 3RecruitingDizal Pharmaceuticals2502025-09-082026-06-03
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia
Phase 3RecruitingBeOne Medicines2502025-04-102026-11-12
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Liso-cel, Idelalisib, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell
Phase 3WithdrawnJuno Therapeutics, Inc., a Bristol-Myers Squibb Company2024-01-162024-04-02
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Pirtobrutinib, Idelalisib, Bendamustine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3Active not recruitingLoxo Oncology, Inc.2382021-03-092026-04-24
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acalabrutinib (ACP-196), Rituximab, Idelalisib - Chronic Lymphocytic Leukemia
Phase 3Active not recruitingAcerta Pharma BV3102017-02-022026-10-23
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Idelalisib - Follicular Lymphoma
Phase 3TerminatedGilead Sciences962016-01-142023-08-14
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Idelalisib, Chlorambucil, Obinutuzumab - Chronic Lymphocytic Leukemia
Phase 3TerminatedGilead Sciences572015-04-212018-11-19
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Idelalisib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia
Phase 3TerminatedGilead Sciences3112014-02-052018-11-19
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Placebo, Rituximab, Idelalisib - Indolent Non-Hodgkin's Lymphomas
Phase 3TerminatedGilead Sciences2952013-01-162018-11-16
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Idelalisib, Rituximab, Bendamustine - Indolent Non-Hodgkin's Lymphomas
Phase 3TerminatedGilead Sciences4752013-01-022018-11-16
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Idelalisib, Ofatumumab - Chronic Lymphocytic Leukemia
Phase 3TerminatedGilead Sciences2612012-12-042019-08-14
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
Idelalisib - Chronic Lymphocytic Leukemia
Phase 3TerminatedGilead Sciences1612012-10-032019-08-20
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
Idelalisib, Rituximab, Bendamustine - Chronic Lymphocytic Leukemia
Phase 3CompletedGilead Sciences4162012-06-152020-03-10
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Idelalisib, Rituximab, Placebo to match idelalisib - Chronic Lymphocytic Leukemia
Phase 3CompletedGilead Sciences2202012-04-012019-05-14

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (13)  ·  Lymphoma, Follicular (3)  ·  Leukemia (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Waldenstrom Macroglobulinemia (2)  ·  Hematologic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)

Sponsors

Gilead Sciences (9)  ·  Acerta Pharma BV (1)  ·  BeOne Medicines (1)  ·  Dizal Pharmaceuticals (1)  ·  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1)  ·  Loxo Oncology, Inc. (1)

Countries

United Kingdom (13)  ·  France (12)  ·  United States (12)  ·  Italy (11)  ·  Australia (10)  ·  Poland (10)  ·  Spain (10)  ·  Canada (9)  ·  Czechia (8)  ·  Germany (8)  ·  Belgium (7)  ·  Hungary (5)  ·  Israel (5)  ·  Russia (5)  ·  South Korea (5)

Top investigators

Marisa Hill, MD (1)  ·  Thomas Jahn, MD (1)

Results publications

PMID 32599655, PMID 24450857, PMID 28257752, PMID 30995176, PMID 31729982, PMID 32459600, PMID 33297794, PMID 33709202, PMID 40479620, PMID 42329537

NIH funding

2015 (2)